Compare DuPont de Nemours Inc (DD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? DuPont de Nemours Inc trades at $134.41 (market cap $18.12B), while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.7× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DD | VRTX | |
|---|---|---|
Market Cap | $18.12B | $120.89B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $529.59 |
52-Week Low | $87.72 | $366.54 |
Enterprise Value | $20.58B | $115.63B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.66, down 1.5% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (35.01%) but negative net income margin (-0.42%) and ROE (-0.16%). Analyst consensus remains bullish with a $227.20 price target (71% upside), though the company faces legal challenges and persistent net cash outflows. Recent developments include water technology upgrades and a 3:1 reverse stock split effective June 2026.
While analyst optimism and valuation discount to price target suggest potential upside, investors face significant risks including ongoing litigation over 'forever chemicals,' weak profitability trends, and concerning cash flow patterns. The stock's current technical weakness near support levels requires careful monitoring of Q2 2026 earnings results due July 2026.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
